Pep2Tango Therapeutics

About

Pep2Tango Therapeutics is a biotech company developing superior unimolecular multi-receptor agonists for obesity and related disorders. Their lead program in obesity is a first-in-class tetra-receptor peptide agonist peptide that shows superiority to Tirzepatide for weight loss in obesity animal models. Other key product differentiation attributes include selective weight loss from fat mass with preservation of lean mass / muscle. With their cutting-edge peptide platform and promising pipeline, Pep2Tango aims to revolutionize obesity and metabolic disease treatment with better, safer, and more effective therapies.

Product

Value proposition

Next generation anti-obesity unimolecular multi-agonist peptides with superior weight loss, preservation of muscle mass, and improved tolerability

Founders

• Cristina Rondinone — Founder, President, CEO and Chairperson
• Soumitra Ghosh — Co-founder and Chief Scientific Officer (CSO)

Products

Key features

Target conditions

Investors

News

• Versant unveils Pep2Tango, a next-gen peptide biotech hoping to redefine obesity treatment · 2024-11-21T16:11:33.000Z
• Versant Ventures Unveils Pep2Tango Therapeutics Inc. · 2024-11-21T13:00:00.000Z
• BioCentury - Versant-backed Pep2Tango taking four-way agonist to clinic for obesity · 2024-11-21T19:13:54.000Z
• Pep2Tango Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials · 2025-12-02T00:00:00.000Z
• Versant startup sets out to make a new type of obesity drug · 2024-11-21T00:00:00.000Z
• Versant startup sets out to make a new type of obesity drug

Browse related software

• Clinic software in MD
• Clinic software in Potomac
• All clinic software companies A–Z